Table 5. – Postoperative pathologic evaluation.
| Variables | Total (n = 111)* | Group 1 (n = 55) | Group 2 (n = 56) | P |
|---|---|---|---|---|
| Gleason Escore: n (%) | 0.497F | |||
| 5 (2+3) | 1 (0.9%) | 1 (1.8%) | - | |
| 5 (3+2) | 2 (1.8%) | - | 2 (3.6%) | |
| 6 (3+3) | 34 (30.6%) | 18 (32.7%) | 16 (28.6%) | |
| 7 (3+4) | 51 (45.9%) | 22 (40.0%) | 29 (51.8%) | |
| 7 (4+3) | 15 (13.5%) | 9 (16.4%) | 6 (10.7%) | |
| 8 (4+4) | 4 (3.6%) | 2 (3.6%) | 2 (3.6%) | |
| 9 (4+5) | 4 (3.6%) | 3 (5.5%) | 1 (1.8%) | |
| Perineural Invasion: n (%) | 27 (24.5%) | 14 (26.4%) | 13 (22.8%) | 0.660 |
| Prostate Capsule Invasion: n (%) | 15 (13.5%) | 5 (9.1%) | 10 (17.9%) | 0.177 |
| Positive Surgical Margin: n (%) | 19 (17.1%) | 8 (16.4%) | 11 (17.9%) | 0.835 |
| Pathological Stage: n (%) | 0.177 |
F = Fisher’s exact test
*= 02 cases with benign prostatic hyperplasia result were excluded and 02 cases in which the operative specimen were lost.